References
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90(3), 262–267 (2006).
- The Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol.122(4), 532–538 (2004).
- European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd Edition. DOGMA srl, Italy (2008)
- Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120(6), 701–713 (2002).
- The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS) 7: the relationship between the control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol.130(10), 429–440 (2000).
- Heijl A, Leske MC, Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120(10), 1268–1279 (2002).
- Robin A, Novack GD, Covert DV et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol.144(10), 533–540 (2007).
- Baudouin C, Liang H, Hamard P et al. The ocular surface of glaucoma patients treated over the long-term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology115(1), 109–115 (2008).
- Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging20(12), 919–947 (2003).
- Iester M. Brinzolamide. Expert Opin. Pharmacother.9(4), 1–10 (2008).
- Holló G. Use of topical carbonic anhydrase inhibition in glaucoma treatment. In: Pharmacotherapy in Glaucoma. Orgül S, Flammer J (Eds). Hans Huber Verlag, Switzerland, 145–152 (2000).
- Holló G. Carbonic anhydrase inhibitors. In: Glaucoma. Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (Eds). Saunders, UK (2009) (In press).
- Bron AJ, Chidlow G, Melena J et al. β blockers in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgül S, Flammer J (Eds). Hans Huber Verlag, Switzerland, 79–113 (2000).
- Kaback M, Scoper SV, Arzeno G et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology115(10), 1728–1734 (2008).
- Manni G, Denis P, Chew P et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2% timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma (2009) (Epub ahead of print).
- Holló G, Chiselita D, Petkova N et al. The efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% each given twice daily added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. Eur. J. Ophthalmol.16(6), 816–823 (2006).
- Holló G, Kóthy P. Intraocular pressure reduction with travoprost/timolol, with and without adjunctive brinzolamide, in glaucoma. Curr. Med. Res. Opin.24(6), 1755–1761 (2008).
- Tsukamoto H, Noma H, Matsuyama S et al. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a β-blocker in patients with glaucoma. J. Ocul. Pharmacol. Therap.21(2), 170–173 (2005).
- Siesky B, Harris A, Cantor LB et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br. J. Ophthalmol.92(4), 500–504 (2008).
- Siesky B, Harris A, Brizendine E et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv. Ophthalmol.54(1), 33–46 (2009).
- Vold SD, Evans RM, Stewart RH et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J. Ocular Pharmacol. Ther.24(6), 601–628 (2008).
- Mundorf TK, Rauchman SH, Williams RD et al. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthalmol.2(3), 623–628 (2008).
- Kanner E, Tsai JC. Glaucoma medications: use and safety in the elderly population. Drugs Aging23(4), 321–332 (2006).
Website
- European Agency for the Evaluation of Medical Products. European public assessment report and product information on Azarga. www.emea.europa.eu/humandocs/Humans/EPAR/azarga/azarga.htm (Accessed 9 January 2009)